Improve data management to improve endpoint adjudication success in clinical trials
In the winter issue of International Clinical Trials, CEO Abraham Gutman writes about how poor management of data is one of the factors ailing adverse event and endpoint adjudication in clinical trials.
The clinical trial industry is transforming, and the vision for this is simple: embrace quality and automation across the clinical trial spectrum and move closer to zero-delay trials. Why? It provides better, faster results, offers more information for sponsors, allows more innovation for CROs, and, most importantly, presents expedited outcomes for patients in need. This transformation is just beginning and requires that we challenge ourselves, our teams, partners, and clients – the entire clinical trial industry – to work smarter and eliminate preventable delays.
To continue reading, click here to access a PDF version of the article.